Contact Us
繁中
簡中
ENG
About

About MicroBase

Certifications and Awards

Intellectual Property

Careers

Social Responsibility

News

Trends


CDMO

Core Technology

Mesh Technology

MicroVibration

Microfluidic Technology

Microneedle Technology


Application

NozzlePlate

Nebulizer & Soft Mist Inhaler

Microneedle

Combination Products

AnalyticLab


Investors

Financial Results

Shareholders Corner

Latest Announcement


Contact

INVESTORS

INVESTORS

Financial Results Shareholders Corner Latest Announcement
MicroBase(3184) FY24 Announcement

Date

Announcements

2024/01/25

Change of representative of legal person director.
2024/03/20

The board of directors approved the consolidated financial statements for the FY24.

2024/03/20

The board of directors resolved to hold the 2024 shareholders meeting related matters.

2024/03/20

The board of directors resolved not to distribute dividends.

2024/09/12

Obtaining Taiwan Medical Device License for LoyalCare Nebulizer System.

 

MicroBase(3184) Obtaining the Taiwan Class II Medical Device License for LoyalCare Nebulizer System

Date : 2024/09/12

Company : MicroBase Technology Corp.

Subject: MicroBase Obtaining the Taiwan Medical Device License for LoyalCare Nebulizer System

Spokesperson: Rick Liu

 

Statement:

1. Date of actual occurrence: 2024/09/12

2. Company name: MicroBase Technology Corp..

3. Relationship with the company (please enter the company or subsidiary): The company

4. Mutual shareholding ratio: Not applicable

5. Reasons for the occurrence: Our company has obtained the Taiwan Food and Drug Administration (TFDA) approval for the LoyalCare Nebulizer System. This nebulizer system is designed for use in intensive care units and long-term care facilities, providing a safe and efficient method of delivering aerosolized medication to patients requiring mechanical ventilation or other positive pressure ventilation support.

6. Response measures: None

7. Other items that should be stated: None

MicroBase(3184) FY23 Announcement

Date

Announcements

2023/08/11

MicroBase applied“Intelligent Drug Delivery System” was approved by Act for the Development of Biotech and Pharmaceutical Industry.

2023/08/10

The board of directors approved the consolidated financial statements for the FY23 half year.

2023/06/19

By-election of a supervisor at the 2023 shareholders annual meeting.

2023/06/19

Important resolutions of the 2023 Shareholders annual meeting.

2023/05/18 

2023 first issuance of employee stock option certificates and share subscription measures.

2023/05/18

The board of directors ratifies and revises the first employee stock option certificate issuance and share subscription method in 2023.

2023/05/15 

Change of representative of legal person director.

2023/03/15

The board of directors resolved not to distribute dividends.

2023/03/15

The board of directors resolved to issue 2023 employee stock option certificates.

2023/03/15

The board of directors resolved to hold the 2023 shareholders meeting related matters.

 

MicroBase(3184) applied“biotech and pharmaceutical company" was approved.

Date : 2023/08/11
Company : MicroBase Technology Corp.
Subject: MicroBase "Intelligent Drug Delivery System" approval of the Act for the Development of Biotech and Pharmaceutical Industry.
Spokesperson: Rick Liu

Statement:
1. Date of actual occurrence: 2023/08/11
2. Company name: MicroBase Technology Corp..
3. Relationship with the company (please enter the company or subsidiary): The company
4. Mutual shareholding ratio: Not applicable
5. Reasons for the occurrence: The company applied to Industrial Development Bureau, Ministry of Economic Affairs for approval as a "biotechnology and pharmaceutical company" with the "Intelligent Drug Delivery System". According to the "Act for the Development of Biotech and Pharmaceutical Industry", the company complies with the "Biotechnology and Pharmaceutical Industry Development Regulations" Article 4, Item 1, Paragraph 2, item 1 and Article 2, Item 1, Paragraph 1 of the "Measures for the Examination and Approval of Biotechnology and Pharmaceutical Companies", and received the approval letter today.
6. Response measures: Announce latest information.
7. Other items that should be stated: None

New Product Approved by China Market

External link: https://ww2.money-link.com.tw/RealtimeNews/NewsContent.aspx?sn=1364570002&pu=News_0046

About News CDMO
Application Core Technology Investors
Brochure Instruction Manual Test Services Process
Privacy Policy Contact Product Warranty

Copyright © MicroBase Technology Corp.

Cookies are used on this website. If you want to inquire about the details of how cookies are used on this website, please refer to the Cookie Statement in the "Privacy Policy " of this website. Your continued use of this website means that you agree that the company may use cookies in accordance with the Cookie Statement of the Terms of Use of this website.